Huntington’s Disease Treatment Market Size to Worth USD 1,217.10 Million by 2032

The global huntington’s disease treatment market size is estimated to be worth around USD 1,217.10 million by 2032, increasing from USD 616.81 million in 2023, a study published by Towards Healthcare a sister firm of Precedence Research.

Ottawa, Feb. 27, 2024 (GLOBE NEWSWIRE) — The global huntington’s disease treatment market size accounted for USD 638.15 million in 2024 and is anticipated to reach around USD 890.18 million by 2029, expanding at a CAGR of 7.8% from 2023 to 2032.

Report Highlights

  • The diagnostic imaging segment ruled the market in 2022 with over 61% market share.
  • Tetrabenzene drugs held the top spot in 2022, capturing 43% of the market.
  • North America remained the kingpin in the huntington’s disease treatment market, with 46% dominance.

Huntington’s disease affects an estimated 2.7 every 100,000 individuals The rising prevalence fosters demand for research and treatment management of huntington’s disease.

Huntington’s disease (HD) is an inherited condition where specific brain cells gradually break down, impacting movement control and various aspects of behavior and emotion. Individuals with huntington’s disease (HD) may experience involuntary dance-like movements called chorea, which can intensify when nervous or distracted. Symptoms typically emerge in middle-aged adults but can also affect children, albeit rarely. The disease progresses, leading to increased movement, balance and cognitive function challenges. In the early stages, signs may manifest as mild clumsiness, balance issues or cognitive and emotional difficulties. Some may face difficulties walking due to chorea, while others might become rigid or experience unusual, fixed postures, known as dystonia. Tremors, abnormal eye movements, slurred speech and problems with swallowing and eating are common physical changes. As HD advances, individuals may face weight loss, fatigue, seizures and eventually require assistance with mobility.

Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5100

Cognitive changes include issues with attention, judgment, decision-making and organizing tasks. Severe cognitive impairment may lead to dementia, hindering daily functioning. Despite these challenges, many people with huntington’s disease (HD) remain aware of their surroundings and can express emotions. Behavioral changes encompass mood swings, irritability, apathy, depression and anger, with some individuals experiencing persistent symptoms like suicidal thoughts and psychosis. Social withdrawal can occur, impacting participation in activities. It is essential to approach HD with empathy, recognizing it as a severe condition requiring comprehensive management. The global demand for effective treatments has increased as awareness of this challenging disorder grows.

Who has a higher risk of developing Huntington’s disease?

  • Huntington’s disease (HD) is inherited, passing from a parent to a child through a gene mutation. If a parent has huntington’s disease (HD), each child has a 50% chance of inheriting the specific chromosome 4 carrying the HD mutation. If a child does not inherit this mutation, they will not develop HD or pass it on.
  • In cases where huntington’s disease (HD) appears without a family history, it’s called sporadic huntington’s disease (HD). The condition is caused by a mutation in the huntingtin gene, leading to an abnormal repetition of DNA building blocks (CAG repeats). Most people have fewer than 27 CAG repeats and aren’t at risk. Those with repeats in the middle range (27 to 35) may not likely develop the disease but could pass it on. People with HD generally have 36 or more CAG repeats.
  • Children of a parent with HD face a 50% chance of inheriting the HD gene. If they don’t inherit it, they won’t develop HD and typically won’t pass it on to future generations. It’s important to understand these genetic factors compassionately.

Huntington’s disease is a genetic disorder affecting the brain, causing movement problems, cognitive decline and emotional issues. Managing symptoms involves medications and support. Innovative solutions, like gene therapies, are being explored for potential future treatments. However, it remains a complex condition to control fully and that’s why scientists focus on more research and treatment.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Huntington’s Disease is More Common, Highlighting the Need for More Research and Treatment

In 2022, according to the Journal of Neurology Research, around the world, about 2.7 out of every 100,000 people are estimated to have huntington’s disease (HD). However, these numbers vary by region, with countries like Canada, the United States, the United Kingdom and Australia having higher prevalence than Asian countries such as Japan, Korea, Taiwan and Hong Kong. In British Columbia, Canada, recent studies suggest a prevalence of 13.7 per 100,000 individuals, slightly lower than the general Caucasian population.

HD is inherited in a way where having one copy of the mutated gene from either parent can lead to the disease. The expansion of a specific DNA sequence in the HD gene causes it. This gene provides instructions for making a protein called huntingtin, found throughout the body, particularly in the central nervous system. While the exact function of huntingtin isn’t fully understood, it’s believed to play essential roles in various cellular processes.

When the DNA sequence expands beyond the normal range, especially with paternal transmission, it can lead to HD. The threshold for developing symptoms is commonly considered when the repeats reach 36 or more, with full-blown symptoms typically seen at 40 repeats or above. More repeats are also linked to an earlier onset of the disease, a faster progression, and increased severity.

Given the global prevalence and demand for management, there’s an increasing need for therapeutic interventions and support for individuals affected by HD.

Huntington’s Disease (HD) is Challenging due to the Genetic Nature of the Disorder

Huntington’s disease is like a puzzle with a specific genetic piece missing or altered. The challenge lies in creating therapies that can precisely target this mutated gene responsible for HD without accidentally affecting the healthy genes around it. Think of it as trying to fix a tiny glitch in a massive computer program without causing any unintended side effects. Our genes are like a well-orchestrated symphony, each playing a unique role. When one gene goes out of tune, as in the case of HD, it can lead to a cascade of issues. Scientists are working to develop treatments that act like skilled musicians, correcting the problematic gene without disturbing the harmony of the entire genetic orchestra.

Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5100

Additionally, this precision work is no easy task. It’s like performing delicate surgery at the molecular level. If the therapy isn’t precise enough, it might unintentionally interfere with other healthy genes, potentially causing more problems than solutions. Here’s where it links to the huntington’s disease treatment market. The complexity of this precision challenge can slow the development of effective therapies. Research and development become more intricate, requiring extensive resources and time. This complexity can decrease the overall market activity for HD treatments as pharmaceutical companies and researchers navigate the intricate landscape of genetic intricacies. So, the difficulty in precisely targeting the root cause of HD without causing collateral damage to healthy genes creates a hurdle in developing treatments, subsequently impacting the market for huntington’s disease therapies.

Browse More Insights of Towards Healthcare:

  • The global brain implants market was valued at USD 5.85 billion in 2022 and is projected to reach around USD 14.24 billion by 2032, expanding at a CAGR of 9.3% between 2023 and 2032.
  • The global lung disease therapeutics market size was valued at USD 81.2 billion in 2022 and is projected to hit around USD 146.1 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032.
  • The global genomics market size to grow from USD 28.9 billion in 2022 to reach around USD 127.16 billion by 2032, registered at a CAGR of 16.1% between 2023 and 2032.
  • The global non-oncology precision medicine market size was at USD 70.16 billion in 2022 and is projected to surpass around USD 163.5 billion by 2032, growing at a CAGR of 8.7% from 2023 to 2032.
  • The global non-invasive blood glucose monitoring system market size to grow from USD 21.76 million in 2022 to reach around USD 202.73 million by 2032, at 25.0% CAGR between 2023 and 2032.
  • The global animal vaccine market was estimated to grow from USD 14.27 billion in 2022 to soar an estimated USD 36.91 billion by 2032, at 10% CAGR between 2023 and 2032.
  • The global pancreatic cancer market size was at USD 2.05 billion in 2022 and is projected to reach around USD 7.4 billion by 2032, expanding at a CAGR of 13.7%.
  • The global 3D Printed prosthetics market size is estimated to grow from USD 1.54 billion in 2022 and is projected around USD 3.28 billion by 2032, expanding at a 7.9 % of CAGR between 2023 and 2032.
  • The global anesthesia monitoring devices market size to grow from USD 2.41 billion in 2022 to reach around USD 5.96 billion by 2032, growing at a CAGR of 9.5% between 2023 and 2032.
  • The global diabetes drugs market was valued at USD 61.87 billion in 2022 and is projected around USD 118 billion by 2032, growing at 6.7% CAGR for 2023 to 2032.

Disease-Modifying Therapy is an Extraordinary Therapy in Huntington’s Disease Treatment

Disease-modifying therapy is like a superhero for the huntington’s disease market. It’s the kind of treatment that doesn’t just tackle the symptoms but goes straight to the root of the problem, aiming to change the course of the disease. Imagine if we could not only ease the symptoms but also slow down or even stop huntington’s disease from getting worse. That’s the magic of disease-modifying therapy! It’s like giving the body and brain a chance to heal and recover. If there’s a therapy that can truly modify the course of the disease, it becomes a beacon of hope for those affected by huntington’s. This increased hope and potential for better outcomes create a growing demand for the therapy, and where there’s demand, the market naturally expands.

Pharmaceutical companies, researchers and healthcare providers also jump on board to support and develop these game-changing therapies. It’s not just about managing the symptoms anymore; it’s about making a real difference in the lives of those dealing with huntington’s disease. So, the pursuit of disease-modifying therapy not only improves the outlook for patients but also propels the market forward with enthusiasm and optimism.

North America’s Dominance Over Other Regions

The North America region plays a significant role in the huntington’s disease treatment market. Advanced healthcare infrastructure, research facilities and a higher prevalence of HD contribute to a robust market. Additionally, ongoing clinical trials and collaborations with pharmaceutical companies contribute to advancements in treatments.

Countries like the United Kingdom, Germany, and France actively participate in HD research and development.

The European Medicines Agency (EMA) regulates therapies, ensuring their safety and efficacy. Collaborations between academic institutions, pharmaceutical companies and healthcare providers drive progress in treatment options.

In Asia-Pacific (Japan, Korea, China), while the prevalence of Huntington’s disease is relatively lower in Asian countries, the market is evolving. Increased awareness, growing healthcare infrastructure and rising research initiatives contribute to expanding the HD treatment market in this region.

Competitive Landscape

The competitive landscape of the huntington’s disease treatment market is characterized by a mix of pharmaceutical companies, biotech firms and research institutions striving to develop innovative therapies. Established pharmaceutical companies with expertise in neurology and genetic disorders play a leading role. These companies invest heavily in research and development to bring novel huntington’s disease treatments to market. Smaller biotech firms often contribute to the competitive landscape by focusing on advanced research and niche therapeutic approaches. Their agility allows for more targeted and innovative solutions in HD treatment. The competitive landscape is dynamic, with advancements in genetic research, neuroscience, and therapeutic development continually influencing the market. As the race to develop disease-modifying treatments intensifies, collaboration, innovation and successful clinical outcomes will be critical factors shaping the competitive dynamics in the Huntington’s disease treatment market.

Recent Developments

  • In 2021, SOM BIOTECH’s drug SOM3355 got a special hug from the U.S. FDA – they granted it an orphan drug title for treating the dance-like moves (chorea) linked to huntington’s disease. It’s like getting a VIP pass for seven years of exclusivity once the FDA gives it a thumbs up.
  • In 2021, Sage Therapeutics’s SAGE-718 was put on a fast track by the U.S. FDA. They got a green light for a quicker route to potentially become a superhero in treating huntington’s Disease.
  • In 2021, F. Hoffmann-La Roche Ltd. hit a roadblock in their study of Tominersen for huntington’s disease. They had to pause dosing in an extensive study called GENERATION HD1 after a careful look at the data by some scientific superheroes known as the Independent Data Monitoring Committee.
  • In 2020, another player joined the game! A company kicked off a phase 2 adventure for ANX005, hoping it could be a hero for HD patients. Meanwhile, the world of stem cell therapy is buzzing with excitement. Cellavita, teaming up with AzidusPharma, is exploring CELLAVITA-HD in an excellent phase 2/3 ADORE-DH trial to see if stem cells could be the key to dance away the troubles of huntington’s disease.

Market Players

  • Apitex Inc.
  • Teva Pharmaceuticals Industries
  • Athena Diagnostic
  • Alnylam Pharmaceuticals
  • Elekta AB
  • Pfizer Inc.
  • SOM BIOTECH
  • Armata Pharmaceuticals, Inc.
  • H. Lundbeck A/S
  • Fulgent Genetics

Market Segments

By Diagnosis Type

  • Diagnostic Imaging
  • Genetic Testing
  • Others

By Drug Type

  • Tetrabenazine
  • Deutetrabenazine
  • Other Drugs

By Treatment Type

  • Symptomatic Therapy
  • Disease-Modifying Therapy
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5100

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Web: https://www.towardshealthcare.com

Browse our Brand-New Journal@ https://www.towardspackaging.com

Browse our Consulting Website@ https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy